GlaxoSmithKline plc vs Smith & Nephew plc: which is the FTSE 100’s best medical marvel?

Royston Wild considers whether investors should pile into FTSE 100 (INDEXFTSE: UKX) giants GlaxoSmithKline plc (LON: GSK) or Smith & Nephew plc (LON: SN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I’m weighing up whether GlaxoSmithKline (LSE: GSK) or Smith & Nephew (LSE: SN) is the better FTSE 100 (INDEXFTSE: UKX) medical pick for savvy stock pickers.

Testing times

Make no mistake: the business of drugs development is a hugely-risky affair, where testing setbacks can lead to lost millions in the case of product delays and cancellations, not to mention a hefty rise in R&D costs.

And for ‘Big Pharma’ plays like GlaxoSmithKline this is a particular problem. The Brentford firm has seen earnings steadily sink during the past five years as key labels have lost patent protection. So bringing on-stream the next generation of sales drivers is critical to get earnings firing again.

GlaxoSmithKline has plans to submit 40 products for regulatory submission during the next decade, around 80% of which the firm believes can lead the industry in their respective fields. However, the scrapping of its IONIS-TTR cardiovascular treatment on safety grounds last month illustrates the hit and miss nature of pharmaceuticals production.

Joints joy

Limbs-and-joints manufacturer Smith & Nephew doesn’t face the same level of unpredictability when it comes to product development, of course. But that’s not to say the bio engineer doesn’t face revenues issues of its own.

Indeed, Smith & Nephew saw sales in emerging markets slump 6% during January-March as uptake from China and the Middle East dived. And prolonged weakness in these critical growth regions could significantly hamper the medical giant’s long-term growth story.

But I believe there’s still plenty to get excited about. Smith & Nephew’s robust position in fast-growing segments like sports medicine continues to generate splendid returns, while acquisition activity is also bolstering the firm’s position in other key areas.

So what does the City think?

The number crunchers certainly believe that Smith & Nephew is in good enough shape to keep earnings growing, and rises of 1% and 12% are pencilled-in for 2016 and 2017, respectively. These produce decent-if-unspectacular P/E ratings of 18.8 times and 17 times.

By comparison, GlaxoSmithKline boasts P/E ratings of 15.6 times and 15.1 times for these periods as earnings are expected to spark again — growth of 16% and 5% is expected this year as analysts put faith in the drugs developer’s product pipeline.

Sure, GlaxoSmithKline may carry a higher risk profile than Smith & Nephew. But I believe both firms have the know-how to deliver splendid earnings growth in the years ahead, particularly as global healthcare investment keeps on surging.

Having said that, dividend chasers may find themselves drawn in by GlaxoSmithKline’s gigantic yields — the City expects the pharma play to make good on planned dividends of 80p per share for this year and next, creating a monster 5.7% yield.

In contrast, Smith & Nephew carries yields of only 2% and 2.2% for these periods thanks to predicted rewards of 21.9p and 24.4p per share.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »